Javascript must be enabled to continue!
Evaluating clinical effectiveness and safety of pneumococcal immunization of infants
View through CrossRef
According to WHO, pneumococcal infection (PI) is considered one of the most dangerous of all vaccine-preventable diseases and, before vaccination, led to the death of up to 1.6 million people per year, of which from 0.7 to 1 million were children. In the prevention of PI, specific prevention occupies a special place. For the first time in 2014, vaccination against PI with pneumococcal conjugate vaccine was included in the national calendar of preventive vaccinations. International practice of using pneumococcal vaccine has shown that timely vaccination can produce positive results in the fight against PI. Under observation were 55 children who were vaccinated against PI with the pneumococcal polysaccharide conjugate vaccine (adsorbed), 13 valent according to the national calendar of preventive vaccinations of the Russian Federation. It was revealed that post-vaccination complications after vaccination did not occur in any child. General post-vaccination reactions were observed in the form of a short-term increase in temperature, loss of appetite and sleep disturbances, as well as local reactions in the form of edema, hyperemia, and hardening at the site of vaccine administration. We studied the incidence of community-acquired pneumonia (CAP), acute otitis media and acute respiratory infections among 55 children of the first year of life vaccinated at 2 months and 4.5 months (main group) and 50 children for various reasons not vaccinated against PI (comparison group). A study of the long-term results of 2-fold vaccination in the first year of life and revaccination at 15 months against PV based on observation of children for two years showed that children of the main group, compared with the comparison group, were 3.3 times less likely to suffer from PV, 2.7 times acute otitis and 1.7 times acute respiratory infections, p < 0.05. The data obtained show the high efficiency and safety of vaccinating children against PI with the pneumococcal vaccine.
Title: Evaluating clinical effectiveness and safety of pneumococcal immunization of infants
Description:
According to WHO, pneumococcal infection (PI) is considered one of the most dangerous of all vaccine-preventable diseases and, before vaccination, led to the death of up to 1.
6 million people per year, of which from 0.
7 to 1 million were children.
In the prevention of PI, specific prevention occupies a special place.
For the first time in 2014, vaccination against PI with pneumococcal conjugate vaccine was included in the national calendar of preventive vaccinations.
International practice of using pneumococcal vaccine has shown that timely vaccination can produce positive results in the fight against PI.
Under observation were 55 children who were vaccinated against PI with the pneumococcal polysaccharide conjugate vaccine (adsorbed), 13 valent according to the national calendar of preventive vaccinations of the Russian Federation.
It was revealed that post-vaccination complications after vaccination did not occur in any child.
General post-vaccination reactions were observed in the form of a short-term increase in temperature, loss of appetite and sleep disturbances, as well as local reactions in the form of edema, hyperemia, and hardening at the site of vaccine administration.
We studied the incidence of community-acquired pneumonia (CAP), acute otitis media and acute respiratory infections among 55 children of the first year of life vaccinated at 2 months and 4.
5 months (main group) and 50 children for various reasons not vaccinated against PI (comparison group).
A study of the long-term results of 2-fold vaccination in the first year of life and revaccination at 15 months against PV based on observation of children for two years showed that children of the main group, compared with the comparison group, were 3.
3 times less likely to suffer from PV, 2.
7 times acute otitis and 1.
7 times acute respiratory infections, p < 0.
05.
The data obtained show the high efficiency and safety of vaccinating children against PI with the pneumococcal vaccine.
Related Results
Sociocultural and geographical disparities in immunization among different geographical regions of Maharashtra
Sociocultural and geographical disparities in immunization among different geographical regions of Maharashtra
Abstract
Background
In Maharashtra, child immunization is an essential factor in maternal and child health services and effective in reduced child morbidity and mortality....
Prevnar 13, the New 13-Valent Pneumococcal Conjugate Vaccine
Prevnar 13, the New 13-Valent Pneumococcal Conjugate Vaccine
Objective: To review the immurtogenicity, efficacy, and safety of the 13-valent pneumococcal conjugate vaccine (PCV13) for use in pediatric patients. Data Sources: A MEDLINE search...
Effects of Pneumococcal Vaccination in Children Under Five Years of Age in the Democratic Republic of Congo: A Systematic Review
Effects of Pneumococcal Vaccination in Children Under Five Years of Age in the Democratic Republic of Congo: A Systematic Review
Background: In the Democratic Republic of Congo (DRC), the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in 2011 through a three-dose schedule, targeting infants ...
FAKTOR YANG BERPENGARUH TERHADAP KELENGKAPAN IMUNISASI DASAR DI WILAYAH KERJA DINAS KESEHATAN KABUPATEN MOJOKERTO
FAKTOR YANG BERPENGARUH TERHADAP KELENGKAPAN IMUNISASI DASAR DI WILAYAH KERJA DINAS KESEHATAN KABUPATEN MOJOKERTO
The immunization program is included in efforts to reduce morbidity, disability and mortality in infants and toddlers. The achievement of complete immunization still has not reache...
Evolving Landscape of Paediatric Pneumococcal Meningitis in Argentina (2013-2023)
Evolving Landscape of Paediatric Pneumococcal Meningitis in Argentina (2013-2023)
The introduction of pneumococcal conjugate vaccination (PCV) into the Argentinian Childhood National Immunization Program in 2012 marked a significant milestone in public health. O...
Evolving Landscape of Paediatric Pneumococcal Meningitis in Argentina (2013–2023)
Evolving Landscape of Paediatric Pneumococcal Meningitis in Argentina (2013–2023)
The introduction of pneumococcal conjugate vaccination (PCV) into the Argentinian Childhood National Immunization Program in 2012 marked a significant milestone in public health. O...
Changes and determinants of pneumococcal vaccine uptake in Ethiopia
Changes and determinants of pneumococcal vaccine uptake in Ethiopia
Abstract
Background:
Pneumococcal pneumonia is one of the most common causes of severe pneumonia and pneumonia-related mortality globally. It is one of the top five causes ...
Evaluating Effects of Culture and Language on Safety
Evaluating Effects of Culture and Language on Safety
This paper (SPE 54448) was revised for publication from paper SPE 48891, prepared for the 1998 SPE International Conference and Exhibition held in Beijing, 2–6 November. Original m...

